Premium
Neutrophil gelatinase‐associated lipocalin in dogs with chronic kidney disease, carcinoma, lymphoma and endotoxaemia
Author(s) -
Cobrin A. R.,
Blois S. L.,
AbramsOgg A. C. G.,
Kruth S. A.,
Dewey C.,
Holowaychuk M. K.,
Gauthier V.
Publication year - 2016
Publication title -
journal of small animal practice
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.7
H-Index - 67
eISSN - 1748-5827
pISSN - 0022-4510
DOI - 10.1111/jsap.12481
Subject(s) - medicine , lipocalin , kidney disease , creatinine , gastroenterology , urine , kidney , urinary system , lymphoma , pathology
OBJECTIVES To measure serum and urine neutrophil gelatinase‐associated lipocalin (NGAL) concentrations in healthy dogs and dogs with chronic kidney disease, neoplasia and endotoxaemia. METHODS Serum and urine NGAL concentrations were measured in 42 healthy dogs, 11 dogs with chronic kidney disease, 12 dogs with carcinoma, 20 dogs with lymphoma and 15 dogs with lipopolysaccharide‐induced endotoxaemia. In dogs with chronic kidney disease, NGAL was measured 3 and 6 months later. RESULTS Compared with healthy controls, dogs with chronic kidney disease (PÄ0·0008), carcinoma (PÄ0·0072) and lymphoma (PÄ0·0008) had elevated serum and urine NGAL and urine NGAL‐to‐creatinine ratio. Serum and urine NGAL was not significantly different between dogs with chronic kidney disease, carcinoma or lymphoma (Pê0·12). In dogs with non‐progressive chronic kidney disease, NGAL concentrations did not change significantly over the 6‐month study period. CLINICAL SIGNIFICANCE NGAL can be elevated by chronic kidney disease and neoplasia, compared with healthy controls. Further research is needed to determine if uNGAL or uNGAL‐to‐creatinine ratio is more specific than serum levels to detect chronic kidney disease.